Taken together, our findings strongly suggest the need for a discussion about the potential benefits of urate-lowering therapy after a diagnosis of hyperuricemia in pediatric-onset patients with ABCG2 dysfunction. The gene discussed is ABCG2; the disease is hyperuricemia.